Citius Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTOR research report →
About the company
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies.
- CEO
- Leonard L. Mazur
- IPO
- 2022
- Employees
- 285
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $63.26M
- P/E
- -1.45
- P/S
- 11.27
- P/B
- 1.93
- EV/EBITDA
- -1.57
- Div Yield
- 0.00%
- Gross Margin
- 80.07%
- Op Margin
- -775.60%
- Net Margin
- -757.57%
- ROE
- -99.47%
- ROIC
- -103.90%
- Revenue
- $0 · 0.00%
- Net Income
- $-24,761,369 · -17.08%
- EPS
- $-0.34 · -13.33%
- Op Income
- $-23,522,750
- FCF YoY
- -4446.73%
- 52W High
- $5.24
- 52W Low
- $0.49
- 50D MA
- $0.81
- 200D MA
- $1.12
- Beta
- 3.42
- Avg Volume
- 88.72K
Get TickerSpark's AI analysis on CTOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 19, 25 | HOLUBIAK MYRON Z | other | 850,000 |
| Sep 19, 25 | HOLUBIAK MYRON Z | other | 100,000 |
| Sep 19, 25 | Smith Robert Joseph | other | 300,000 |
| Sep 19, 25 | Mazur Leonard L | other | 1,700,000 |
| Sep 19, 25 | Webb Carol | other | 300,000 |
| Sep 19, 25 | Czuczman Myron | other | 825,000 |
| Sep 19, 25 | MCGRATH DENNIS M | other | 300,000 |
| Sep 19, 25 | Bartushak Jaime | other | 825,000 |
| Sep 19, 25 | Mayersohn Joel David | other | 300,000 |
| Sep 19, 25 | Dutia Suren G | other | 300,000 |
Our CTOR coverage
Recent articles, reports, and earnings notes.
No research on CTOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTOR report →Similar companies
Peers in the same neighborhood.